000			03452nam a22004217a 4500
008			240723s20242024 xxu||||| |||| 00| 0 eng d
022			_a1383-875X
024			_a10.1007/s10840-024-01791-1 [pii]
040			_aOvid MEDLINE(R)
099			_a38509402
245			_aEarly real-world implant experience with a helix-fixation ventricular leadless pacemaker.
251			_aJournal of Interventional Cardiac Electrophysiology. 2024 Mar 20
252			_aJ Interv Card Electrophysiol. 2024 Mar 20
253			_aJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
260			_c2024
260			_p2024 Mar 20
265			_saheadofprint
265			_tPublisher
266			_d2024-07-23
520			_aBACKGROUND: Roughly one in six patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. In this study, the initial real-world implant experience of the helix-fixation LP was evaluated following its commercial release.
520			_aCONCLUSIONS: The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications. Copyright © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
520			_aMETHODS: In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated.
520			_aRESULTS: A total of 167 patients with Class I indication for permanent pacing received implants in four North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 OMEGA [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events.
546			_aEnglish
650			_zAutomated
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aElectrophysiology
657			_aJournal Article
700			_aEldadah, Zayd _bMHVI
700			_aHadadi, Cyrus A _bMWHC
700			_aIslam, Malick _bMHVI
700			_aThomaides, Athanasios _bMWHC
790			_aNair DG, Exner DV, Reddy VY, Badie N, Ligon D, Miller MA, Lee B, Doty B, Thomaides A, Eldadah Z, Islam M, Hadadi C
856			_uhttps://dx.doi.org/10.1007/s10840-024-01791-1 _zhttps://dx.doi.org/10.1007/s10840-024-01791-1
942			_cART _dArticle
999			_c14205 _d14205